We'd like your feedback
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.
Low risk thyroid cancers
This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.
Background and study aims
The rate of well-differentiated thyroid cancer (DTC) is increasing faster than any other tumour. The current standard treatment for low-risk DTC is surgical removal of the whole thyroid gland called total thyroidectomy (TT), followed by radioiodine treatment. More recently, surgeons have started performing hemithyroidectomy (HT) (removal of the cancerous half of the thyroid) as international guidelines changed and studies suggested patients may benefit from less extensive surgery, whilst maintaining excellent cure rates. HT patients may not require life-long hormone replacement therapy, calcium and vitamin D supplements, and radioiodine treatment. However, results from these studies are biased and conflicting. There is uncertainty surrounding the most appropriate surgery causing variations in practice between different teams and hospitals.
HoT is the first trial to directly compare TT versus HT in terms of the rate of cancer returning, impact on quality of life, surgery-related side-effects, need for thyroid hormone replacement therapy after surgery, health resources use and cost-effectiveness to the NHS.
Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.
The recruitment start and end dates are as follows:
You can take part if:
You may not be able to take part if:
Group 1 (Hemithyroidectomy already performed prior to diagnosis):1. Tumour > 4cm2. Unifocal pT1a (< = 1cm) papillary thyroid cancer (PTC) and follicular thyroid cancer (FTC) (unless pN1a as listed in inclusion criteria)3. Non-invasive encapsulated follicular variant of PTC4. Anaplastic, poorly differentiated or medullary thyroid carcinoma5. R2 resection6. Gross extrathyroidal extension 7. pT4 or macroscopic tumour invasion of loco-regional tissues or structures8. pN1a with > 5 foci or extranodal spread9. pN1b 10. M1 11. Aggressive PTC with any of the following features: - Widely invasive - Poorly differentiated - Anaplastic - predominance of Tall cell, Columnar cell, Hobnail, Diffuse sclerosing and other higher risk variants 12. FTC and oncocytic/Hürthle cell cancer with any of the following features: - Minimally invasive with extensive vascular invasion (now called encapsulated angioinvasive) (> 4 foci) - Widely invasive - Poorly differentiated - Anaplastic
Group 2 (Differentiated thyroid cancer on cytology or after core biopsy, who has not had prior thyroid surgery yet)1. M1
Below are the locations for where you can take part in the trial. Please note that not all sites may be open.
Mrs
Aniqa
Tasnim
+44 (0)20 3108 4753
ctc.hot@ucl.ac.uk
The study is sponsored by University College London and funded by NIHR Evaluation, Trials and Studies Co-ordinating Centre (NETSCC); National Institute for Health Research (NIHR) (UK).
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Or CPMS 48988
You can print or share the study information with your GP/healthcare provider or contact the research team directly.
